Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering

5 Feb 2025

Abstract excerpt

The rapid evolution of the viral genome has led to the continual generation of new variants of SARS-CoV-2. Developing antibody drugs with broad-spectrum and high efficiency is a long-term task. It is promising but challenging to develop therapeutic neutralizing antibodies (nAbs) through in vitro evolution based on antigen-antibody binding interactions. From an early B cell antibody repertoire, we isolated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39908098
DOI: 10.1073/pnas.2406659122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineeringPMID 39908098Read ↗

Computationally restoring the potency of a clinical antibody against Omicron.Semantic proximity Read ↗

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariantsSemantic proximity Read ↗

The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution.Semantic proximity Read ↗

Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron VariantsSemantic proximity Read ↗

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responsesSemantic proximity Read ↗

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariantsSemantic proximity Read ↗

Potent, Omicron-Neutralizing Antibodies Isolated From a Patient Vaccinated 6 Months Before Omicron EmergenceSemantic proximity Read ↗

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsSemantic proximity Read ↗

Potent cross-reactive antibodies following Omicron breakthrough in vaccineesSemantic proximity Read ↗

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsSemantic proximity Read ↗

Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variantsSemantic proximity Read ↗

Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.